Cumulative Effects of Vicadrostat and Empagliflozin on Albuminuria in CKD

American Journal of Kidney Diseases 2026 Open access

Read full text
Authors: Peter Rossing, Sibylle Jenny Hauske, Maria Eugênia Canziani, Maria Luiza Caramori, D Cherney, Ricardo Correa-Rotter, Christian Hugo, Masaomi Nangaku, Arnold Silva, Dorothea Urbach, Dick de Zeeuw, Juliane Meyerhoff
+4 more Lisa Cronin, Zhichao Sun, Shimoli V. Shah, Katherine R. Tuttle
DOI: 10.1053/j.ajkd.2025.11.009
Cited by: 1
References: 10

Abstract

Aldosterone excess may lead to accelerated chronic kidney disease (CKD) progression, elevated blood pressure (BP), and an increased risk of cardiovascular events.1,2 The mechanisms of kidney and cardiovascular injury by aldosterone include fibrosis, inflammation, and dysfunctional remodeling.3 Renin-angiotensin system (RAS) inhibitors and nonsteroidal mineralocorticoid receptor antagonists are beneficial for treatment of CKD but may not fully block harmful effects of aldosterone. This may be achieved by targeting aldosterone synthase (AS; CYP11B2), the enzyme that mediates the final steps in aldosterone synthesis.

Fields of Study & Subjects

Diabetes Treatment and Management Chronic Kidney Disease and Diabetes Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
American Journal of Kidney Diseases
Publisher
Elsevier BV
Volume
87
Issue
5
Pages
704–708
Publication date
10 February 2026
Language
EN